3Neuprez A,Hiligsmann M,Scholtissen S. Strontium ranelate:the first a-gent of a new therapeutic class in osteoporosis[J].{H}Advances in therapy,2008,(12):1234-1256.
3IMANISHI Y,NISHIZAWA Y,Strontium ranelate as new therapeutic agent for osteoporosis[J].Clin Calcium,2005,15(1):25-33.
4WIERZBICKI M,BONNET J,BRISSET M,et al.Bivalent metal salts of 2-[N,N-di (carboxymethyl) aminol]-3-cyano-4-carboxymethyhhiophene-5-carbox-ythiopheneacidprocess for their preparation and pharmaceutical compsns:US 5128367[P].1990-8-31.
5MICHEL W,DENISE C,PAUL C.Appliationla synth se de quelques thieno[2,3-b] pyrroles[J].Bull Soc Chim Fr,1975(7-8):1786-1792.
6VAYSSE L L,LECOUVE J P,LANGLOIS P.New process for industrial synthesis of strontium ranelate and its hydrates:FR 200211763[P].2002-09-24.
7FANG N T.Events of Organic Synthesis(有机合成事典)[M].Beijing:Institute of Technology Press,1992:341-342.
9Hodsman AB, Bauer DC, Dempster D, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis : a review of the evi- dence and suggested guideline for its use[J]. Endocr Rev, 2005, 26 (5) : 688-703.
10Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation[J]. Eur J Pharmacol, 2002, 450(1): 11-17.
